The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | SOREGATT: sequencing regorafenib & trifluridine/tipiracil in pre-treated mCRC
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses findings from the Phase II PRODIGE 68 – UCGI 38 – SOREGATT trial (NCT04450836) of regorafenib and trifluridine/tipiracil in patients with metastatic colorectal cancer (mCRC), who have progressed on standard therapies. Patients were randomized to receive regorafenib then trifluridine/tipiracil or the other way round. The order of therapy did not affect overall survival and progression-free survival. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
